Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Int131 SCHEMBL30035369 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL29404335 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL634767 | 0.91 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL635008 | 0.90 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL24268600 | 0.86 | PPARG (0.87) | PPARGCYP3A4 | |
| SCHEMBL22515346 | 0.86 | PPARG (0.87) | PPARGCYP3A4 | |
| SCHEMBL22515271 | 0.85 | PPARG (0.84) | PPARGCYP3A4 | |
| Int131 SCHEMBL634435 | 0.84 | PPARG (0.86) | PPARGCYP3A4 | |
| SCHEMBL22203939 | 0.82 | PPARG (0.83) | PPARGCYP3A4 | |
| SCHEMBL7996313 | 0.82 | PPARG (0.83) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218604-A1 | PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY | Coherus Biosciences, Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218604-A1 | PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY | PPARA, PPARG, PPARD | PPARG 2/4885CYP3A4 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.